SCHEMBL6499211

SCHEMBL6499211

N#Cc1ccccc1CN1CCc2cc(NC(=O)C3=C(c4ccc(C(F)(F)F)cc4)CCCC3)ccc2C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
NOD1 Q9Y239 4/20 0.41
GAA P10253 1/20 0.41
TNF P01375 3/20 0.41
NOD2 Q9HC29 3/20 0.41
DRD2 P14416 2/20 0.41
DRD3 P35462 2/20 0.41
KDR P35968 1/20 0.40
PRKAA2 P54646 1/20 0.39
KCNJ1 P48048 1/20 0.39
ACACB O00763 1/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
DRD1 P21728 1/20 0.39
DRD4 P21917 1/20 0.39
DRD5 P21918 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497091 0.86 PRKAA2 (0.52) MEN1KMT2ARAB9ANPC1NOD1
SCHEMBL6498841 0.85 CLPP (0.52) MEN1KMT2ARAB9ANPC1NOD1
SCHEMBL6489208 0.82 NOD1 (0.41) MEN1KMT2ARAB9ANOD1TNF
SCHEMBL6489620 0.81 ABCB1 (0.51) NOD1TNFDRD2HIF1AEPAS1
SCHEMBL6501845 0.81 NOD1 (0.47) MEN1KMT2ARAB9ANPC1NOD1
SCHEMBL6491162 0.81 NOD1 (0.48) MEN1KMT2ARAB9ANOD1TNF
SCHEMBL6498924 0.79 SRPK1 (0.44) NOD1TNFNOD2ACACBHIF1A
SCHEMBL6502283 0.79 NOD1 (0.40) MEN1KMT2ARAB9ANPC1NOD1
SCHEMBL6498359 0.79 TNF (0.49) NOD1TNFNOD2DRD3ACACB
SCHEMBL6490877 0.79 MTTP (0.45) NOD1TNFNOD2KDRACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 MEN1 1991/4885KMT2A 573/4885RAB9A 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.